Slamon DJ - Search Results

1

Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.

Pegram MD, Slamon DJ. Pegram MD, et al. Among authors: slamon dj. Semin Oncol. 1999 Aug;26(4 Suppl 12):89-95. Semin Oncol. 1999. PMID: 10482199 Clinical Trial.

2

HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. Pietras RJ, et al. Among authors: slamon dj. Oncogene. 1995 Jun 15;10(12):2435-46. Oncogene. 1995. PMID: 7784095

3

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

Press MF, Hung G, Godolphin W, Slamon DJ. Press MF, et al. Among authors: slamon dj. Cancer Res. 1994 May 15;54(10):2771-7. Cancer Res. 1994. PMID: 7909495

4

Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.

Karlan BY, Jones J, Slamon DJ, Lagasse LD. Karlan BY, et al. Among authors: slamon dj. Gynecol Oncol. 1994 Apr;53(1):70-7. doi: 10.1006/gyno.1994.1090. Gynecol Oncol. 1994. PMID: 7909787

5

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Pietras RJ, et al. Among authors: slamon dj. Oncogene. 1994 Jul;9(7):1829-38. Oncogene. 1994. PMID: 7911565

6

HER-2/neu signal transduction in human breast and ovarian cancer.

Reese DM, Slamon DJ. Reese DM, et al. Among authors: slamon dj. Stem Cells. 1997;15(1):1-8. doi: 10.1002/stem.150001. Stem Cells. 1997. PMID: 9007217 Review.

7

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.

Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. Pegram MD, et al. Among authors: slamon dj. Oncogene. 1997 Jul 31;15(5):537-47. doi: 10.1038/sj.onc.1201222. Oncogene. 1997. PMID: 9247307

8

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. Press MF, et al. Among authors: slamon dj. J Clin Oncol. 1997 Aug;15(8):2894-904. doi: 10.1200/JCO.1997.15.8.2894. J Clin Oncol. 1997. PMID: 9256133

9

Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.

Landgraf R, Pegram M, Slamon DJ, Eisenberg D. Landgraf R, et al. Among authors: slamon dj. Biochemistry. 1998 Mar 3;37(9):3220-8. doi: 10.1021/bi972326z. Biochemistry. 1998. PMID: 9485477

10

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Pegram MD, et al. Among authors: slamon dj. J Clin Oncol. 1998 Aug;16(8):2659-71. doi: 10.1200/JCO.1998.16.8.2659. J Clin Oncol. 1998. PMID: 9704716 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters